Looking beyond the drug receptor for clues to drug effectiveness
Durham, N.C. 26 August 2008  Antipsychotic drugs that are widely used to treat schizophrenia and other problems may not work as scientists have assumed, according to findings from Duke University Medical Center researchers that could lead to changes in how these drugs are developed and prescribed. Scientists have known that all antipsychotic drugs target the D2 receptor inside cells. New tests developed at Duke reveal that the biochemical pathways linked to this receptor - the pathways along which the drugs deliver their therapeutic effects - may function differently than previously understood.
---------------------------------------------------------------------------------------------------------
Chemokine Therapeutics Receives Approval From Hong Kong to Commence Phase II Study in Liver Cancer
Vancouver, BC 21 August 2008  Chemokine Therapeutics Corp. (the “Company”) (TSX:CTI, OTCBB:CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, announced today that it has received a Certificate for Clinical Trial/Medicinal Test from the Hong Kong Department of Health allowing the Company to begin a Phase II trial in liver cancer with its lead drug candidate, CTCE-9908. The Company received FDA and Health Canada approval for the clinical trial earlier this year.
---------------------------------------------------------------------------------------------------------
HSC-Institute of Biosciences and Technology researchers learn about role of mutated DNA repeats in diseases like cancer
Houston 21 August 2008  Researchers at the Texas A&M Health Science Center Institute of Biosciences and Technology in Houston have uncovered new information about the role of certain mutated segments of DNA in forming diseases like cancer. This finding could someday lead to therapies targeting the mutated DNA segments.
---------------------------------------------------------------------------------------------------------
Enobia Pharma initiates clinical testing of Enzyme Replacement Therapy to treat hypophosphatasia
Montreal 20 August 2008  Enobia Pharma, an emerging Canadian biotech company focused on developing novel therapeutics for serious bone disorders, today announced that the first patient in its clinical program for hypophosphatasia has been dosed. Enobia is investigating Enzyme Replacement Therapy (ERT) with ENB-0040 for the treatment of this rare and often crippling genetic bone disorder for which there is no approved treatment.
---------------------------------------------------------------------------------------------------------
BIO Supports EPA Denial of Renewable Fuel Standard
Washington, D.C. 07 August 2008  The Renewable Fuel Standard (RFS) provides crucial support and incentives for companies to invest in new biorefineries to bring advanced biofuels to the pump. Biotechnology Industry Organization (BIO) President & CEO Jim Greenwood released the following statement expressing the industry’s support for the U.S. Environmental Protection Agency’s decision not to grant Texas Gov. Rick Perry’s petition to cut the RFS.
--------------------------------------------------------------------------------------------------------- |
